HC Wainwright & Co. Reiterates Buy on Syndax Pharmaceuticals, Maintains $38 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado has reiterated a Buy rating on Syndax Pharmaceuticals (NASDAQ: SNDX) and maintained a price target of $38 for the stock.